ABWN like I said before... they told investors that toxic

New Post Public Reply Private Reply Replies (1) Message Board
BionicBen
1,088
ABWN like I said before... they told investors that toxic financing was going to run this down to .25 aka -82.5% dilution... But now you have panic and it dropped to a penny. I think this will bounce back and hopefully we will hear something good about what was done with the money gained from the dilution.

FROM 6/5/18 POST:
https://investorshangout.com/post/view?id=5075074

This means the stock manipulation has been completed and we should be at bottom. GREAT find here. You can see that they were in talks and considering this option well in advanced of the filing date of 5/29/18. This is why and how the share price has dropped so much. Stock price was at $2.60 approx and they knew that the price was going to drop well below a dollar by may 2018, and basically expected it to hit the bottom at .25. Only the insiders knew the price was going to drop. Hopefully they are clean and did not profit from this. There is such thing as legal insider trading but it is between the executives and certain share holders and it usually never effects the common stock. This article however, is basically saying that once these preferred shares get converted the stock price will hit no lower than .25 (down 82.5%???) and IMO we are seeing it drop lower because anyone who does not understand this is now freaking out and just wants out because this could keep dropping to trips. I think .20 is close to the new floor. I expect news in the next 3-9 months to bring the price back up to around $1. jmho based off this letter and the chart.


https://finance.yahoo.com/news/airborne-wirel...rc=applewf
(...Each share of Preferred Stock is being sold together with (i) one Series 1 Warrant to purchase one share of Preferred Stock, (ii) one Series 2 Warrant to purchase one share of Preferred Stock, and (iii) one Series 3 Warrant to purchase one share of Preferred Stock. The Preferred Stock has an initial stated value of $1,150 and is convertible into shares of the Company's common stock at a conversion price equal to the lesser of (a) $0.71, subject to certain adjustments, or (b) 82.5% of the lowest volume weighted average price of the Company's Common Stock during the five trading days ending on, and including, the date of the notice of conversion. For the first 15 calendar days following the filing of the certificate of designations for the Preferred Stock, the conversion price is subject to a floor of $0.25 per share, except in the event of anti-dilution adjustments. Each Warrant will have an initial exercise price of $1,000 per share of Preferred Stock. The Series 1 Warrants, Series 2 Warrants and Series 3 Warrants will be immediately exercisable and will expire on the three-month, six-month, and twelve-month anniversary of the original issuance date, respectively...)

The Offering is expected to close on May 29, 2018, subject to the satisfaction of customary closing conditions.

https://www.investopedia.com/terms/i/insidertrading.asp
Illegal insider trading includes tipping others when you have any sort of nonpublic information. Legal insider trading happens when directors of the company purchase or sell shares, but they disclose their transactions legally.


Read More: https://investorshangout.com/post/view?id=507...z5IsvXejrN
Disclaimer:
There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator.
Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.
There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in all and any posts.
My posts are NOT investment advice. I am not paid to post.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading

Top 5 Most Recently Viewed Articles

BioXcel Therapeutics Faces Challenges Amidst 52-Week Low

Updated Category News Views 85

BioXcel Therapeutics: Facing the Heat BioXcel Therapeutics Inc. (BTAI) is in the doghouse—its stock just hit a jaw-dropping 52-week low of $0.53. That's an eye-watering drop of over 80% in the last year. Investors are glued to their screens, weighing whether to grab some shares at rock-bottom prices or steer clear as BioXcel grapples with mounting obstacles. This sharp...

Continue Reading
Guidehouse Welcomes Ron White as New Chief Information Officer

Updated Category News Views 315

Guidehouse Appoints Ron White as Chief Information Officer Advancing the firm's AI-led strategy with visionary leadership to drive business transformation and scalable innovation MCLEAN, Va. – Guidehouse, a global AI-led professional services firm, has recently appointed Ron White as its Chief Information Officer (CIO). With over 35 years of expertise in enterprise...

Continue Reading
Natural Ingredients Driving Growth in Cosmetics Market

Updated Category News Views 186

Market Growth Driven by Consumer Demand Recent studies indicate that the chemicals market for cosmetics and toiletries is experiencing significant growth. The market is set to increase from $27.7 billion to an impressive $35 billion by the end of 2029. This momentum speaks volumes about the trends affecting consumer preferences and the investment patterns of leading...

Continue Reading
Securities Investigation Alert for Semler Scientific Investors

Updated Category News Views 118

Understanding the Semler Scientific Investigation The Rosen Law Firm is actively investigating potential securities claims for investors of Semler Scientific, Inc. (NASDAQ: SMLR). This initiative addresses concerns regarding the possibility that the company may have provided significantly misleading information about its business practices to the public. Why You Should Be...

Continue Reading
Exciting Updates from Bitget Wallet: Join Fomo Thursdays

Updated Category News Views 390

Bitget Wallet Introduces Fomo Thursdays Events Bitget Wallet, a prominent non-custodial crypto wallet, is thrilled to announce the launch of its fourth Fomo Thursdays event, brought to life in collaboration with Velo Protocol. This event focuses on broadening participation in the crypto space, featuring a staggering prize pool of 3.47 million VELO tokens and 50,000 slots...

Continue Reading